Pipeline
Phase II/III
CT053 is a BCMA-specific CAR T product candidate, consists of autologous T cells genetically modified with a CAR incorporating a fully human anti-BCMA single chain fragment variant with high binding affinity that specifically recognizes BCMA.
Investigator-Initiated Trial in China
Phase I/II Clinical Trial for MM in China (LUMMICAR STUDY 1)
Phase Ib/II Clinical Trial for MM in North America (LUMMICAR STUDY 2)
for relapsed and/or refractory multiple myeloma (R/R MM)
for relapsed and/or refractory multiple myeloma (R/R MM)
Breakthrough Therapy Designation, NMPA
for relapsed and/or refractory multiple myeloma (R/R MM)
for multiple myeloma (MM)
Orphan Drug designation, EMA
for multiple myeloma (MM)
CT041 is an autologous CAR T product candidate that targets Claudin18.2 (“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.
Investigator-initiated trials
Phase Ib clinical trial for advanced GC/GEJ and PC
Confirmatory Phase II clinical trial for advanced GC/GEJ
for advanced gastric /gastroesophageal junction adenocarcinoma (GC/GEJ) with Claudin18.2-positive tumor
for advanced gastric cancer
for gastric /gastroesophageal junction cancer (GC/GEJ)
Orphan Drug designation, EMA
for advanced gastric cancer
CT011 is an autologous CAR T product candidate that targets glypican-3 (GPC3), which is highly expressed in HCC and is suggested to be a prognostic marker for the disease.
Investigator-Initiated Trial for HCC
Phase I Clinical Trial for HCC
Phase II/III
AB011 is a humanized monoclonal antibody product candidate that targets Claudin18.2(“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.
Phase I Clinical Trial for CLDN18.2 Positive Advanced Solid Tumors
* Denotes our Core Product Candidate;
** Rights in the South Korean market has been licensed out to HK Inno.N (KOSDAQ: 195940);
*** Phase II trials of some indications are pivotal studies;
R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; PC: pancreatic cancer; B-cell non-Hodgkin lymphoma; GEJ: gastroesophageal junction cancer; HCC: hepatocellular carcinoma cancer.